Lipids Profile in Subclinical Hypothyroidism (LPSH)
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Overt hypothyroidism is associated with increased risk for cardiovascular disease (CVD) as indicated by hypertension, hypercholesterolemia, and increased low-density lipoprotein cholesterol (LDL-C) levels. Mild hypothyroidism, also called subclinical hypothyroidism [SH] is highly prevalent in elderly subjects, especially in women older than 50 years of age. Whether SH is related as a risk for premature CVD is controversial. It was shown that SH is associated with elevated lipids levels, particularly LDL-cholesterol. However recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL-cholesterol exerts a direct influence on the cardiovascular risk. LDL-cholesterol comprises multiple distinct subclasses that differ in their atherogenic potential. Thus, the proposed study protocol is intended to evaluate the different LDL lipoproteins subclasses in patients with subclinical hypothyroidism.
| Condition | Intervention |
|---|---|
|
Subclinical Hypothyroidism |
Procedure: laboratory analysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism |
- Evaluation of atherogenic lipoproteins [ Time Frame: enrollment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | October 2009 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
subclinical hypothyroidism
Patients with subclinical hypothyroidism
|
Procedure: laboratory analysis
laboratory analysis
|
Detailed Description:
Overt hypothyroidism is associated with increased risk for cardiovascular disease[CVD] as indicated by hypertension, hypercholesterolemia, and increased low-density lipoprotein cholesterol (LDL-C) levels.However, not all patients have hypertension or abnormal lipid profiles, suggesting that other factors may be involved as collagen-induced platelet aggregation or relaxation of vascular smooth muscle, elevated plasma homocysteine and C- reactive protein [CRP] levels have been reported in overt hypothyroidism and have been proposed as an independent risk factor for CVD.
Subclinical hypothyroidism [SH] is highly prevalent in elderly subjects, especially in women older than 50 years of age. Whether SH is related as a risk for premature CVD is controversial. Previously, we have demonstrated that SH in middle-aged women is associated with hypertension, hypertriglyceridemia, and elevated total cholesterol/HDL- cholesterol ratio.SH was associated with elevated plasma total cholesterol and LDL-cholesterol, decreased LDL-cholesterol/LDL-triglycerides due to decreased hepatic lipase activity. The influence of SH on lipids was directly proportional to the degree of TSH elevation.
Atherosclerosis is a diffuse disease formerly considered lipid storage disease, actually involves an ongoing inflammatory response. Elevated circulating levels of acute phase proteins, cytokines, and cell adhesion molecules indicate that inflammatory processes are occurring systematically. Metabolic syndrome is a collection of metabolic risk factors, probably of more than one cause, that appear to promote the development of atherosclerotic CVD. Hypertension, dyslipidemia and hyperglycemia are the most widely recognized characteristics of the metabolic syndrome. Individuals with metabolic syndrome manifest a prothrombotic state as well as a proinflammatory state. Insulin resistance is recognized as a chronic low-level inflammatory state. Insulin action is an important effector mechanism of the proinflammatory cytokines in CVD. Insulin resistance was proposed as the common preceding factor of hypertension, LDL and HDL-cholesterol, hypertriglyceridemia, abdominal obesity and altered glucose metabolism, linking all of these to the development of CVD. Thus, inflammation, metabolic syndrome and insulin resistance are strongly associated and play an important role in the pathogenesis of atherosclerosis. In a cross-sectional analysis, subjects with SH had a significantly higher prevalence of CVD than euthyroid subjects. There were more cardiovascular deaths in subjects with SH than in the euthyroid population. These data suggest that SH may be an independent risk factor for CVD. It is not clear yet whether patients with SH have cardiovascular risk, as do patients with overt hypothyroidism, and whether metabolic syndrome and insulin resistance already exist in untreated patients with SH.
This question was recently studied by our group. We evaluated untreated patients with SH. the percentage of MS in patients (41.5%) was significantly higher than in controls (12.2%; p=0.003]. SH had significantly higher likelihood of cardiovascular risks [odds ratio 6.26, 95% confidence interval (CI) 1.6 - 4.49, p= 0.008 for MS].
We conclude that SH is associated with greater probability of MS. Recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL exerts a direct influence on the cardiovascular risk. LDL comprises multiple distinct subclasses that differ in size, density, physicochemical composition, metabolic behaviour and atherogenicity. There are at least four major subspecies of LDL (e.g. large LDL-I, medium LDL-II, small LDL-III, very small LDL-IV) and the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor.
Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with subclinical Hypothyroidism.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients followed at the Endocrine Institute, Haemek Medical Center, Afula, Israel
Inclusion Criteria:
- Subjects with subclinical hypothyroidism
Exclusion Criteria:
- Patients taking L-thyroxin therapy
- Patients with known cardiovascular, cerebral or peripheral atherosclerotic disease.
Contacts and Locations| Contact: Avraham Ishay, MD | 972-4-6495556 ext 5556 | ishay_av@clalit.org.il |
| Israel | |
| Endocrine Institute, Haemek Medical Center | Not yet recruiting |
| Afula, Israel, 18101 | |
| Study Director: | Rafael Luboshitzky, MD | Endocrine Institute, Haemek Medical Center, Afula, Israel |
| Study Chair: | Manfredi Rizzo, MD | University of Palermo |
| Study Chair: | Giatgen Spinas, MD | University of Zurich |
| Study Chair: | Kaspar Berneis, MD | University of Zurich |
More Information
No publications provided
| Responsible Party: | Avraham Ishay, MD, HaEmek Medical Center, Israel |
| ClinicalTrials.gov Identifier: | NCT00962221 History of Changes |
| Other Study ID Numbers: | 0099.09EMC |
| Study First Received: | August 18, 2009 |
| Last Updated: | September 9, 2009 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by HaEmek Medical Center, Israel:
|
LDL lipoprotein subclasses in subclinical hypothyroidism |
Additional relevant MeSH terms:
|
Hypothyroidism Thyroid Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013